Sage and Biogen File NDA for Fast-Acting Postpartum Depression Drug

Posted by ISPE Boston
On February 10, 2023

Collaboration partners Sage Therapeutics and Biogen have announced that the FDA has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The […]

Pharma Giant Seqens Opens New R&D Facility in Devens

Posted by ISPE Boston
On February 10, 2023

Joined by a coalition of local legislators, including state Sen. Jamie Eldridge and members of the Devens Enterprise Commission, the $1.4 billion French biotech and pharmaceutical giant celebrated the completion of and move to a “state-of-the-art” research and development facility at 67 Buena Vista Street, replacing a smaller facility on Jackson Road. Seqens President and […]

A Winter Social Extravaganza!

Posted by ISPE Boston
On February 3, 2023

Last night’s Winter Social was a huge success! Thank you to everyone who showed up and made this event as amazing as it was! We had over 130 attendees and everyone had a wonderful time networking, eating delicious food and drinking fun beverages with crazy twisty straws! We couldn’t have asked for a better venue […]

Chapter Member Anniversaries: February 2023

Posted by ISPE Boston
On February 2, 2023

Please congratulate the following members celebrating milestone anniversaries in February 2023. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years John Alleruzzo, Retired William Crowe, Strawbridge Crowe Scott Ripatrazone, Insco Group Kenneth Bradley, Pfizer Eric Good, ProPharma Group Richard Moreton, FinnBrit Consulting James Crotty, Continuus Pharmaceuticals Michael Matton, […]

Welcome New Members January 2023!

Posted by ISPE Boston
On February 2, 2023

We would like to introduce the Members who joined ISPE in January 2023, welcome them to the Chapter and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

Ipsen to Acquire Albireo for $952 Million

Posted by ISPE Boston
On January 27, 2023

French drugmaker Ipsen plans to acquire Cambridge-based Albireo in a deal worth about $952 million. Albierio is developing bile-acid modulators to treat pediatric and adult cholestatic liver diseases. The company was spun out from AstraZeneca in 2008 and is headquartered in Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The anticipated acquisition will enrich […]

HIV Vaccine Fails in Phase 3 Trial

Posted by ISPE Boston
On January 27, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, have announced discontinuation of its HIV vaccine Phase 3 clinical trial based on the results of an independent data review by the study’s independent Data and Safety Monitoring Board (DSMB). The review determined that the HIV vaccine regimen was not […]

2023 Product Show – Call for Presentations!

Posted by ISPE Boston
On January 26, 2023

Are you getting excited for this year’s Product Show?! It’s that time of year again where we ask for Presentation Proposals from you! Read more on how this works below: The ISPE Boston Area Chapter will hold its 31st Annual Product Show on September 20, 2023 at Gillette Stadium in Foxborough, MA. This notice is […]

Vertex and Entrada in Deal to Collaborate

Posted by ISPE Boston
On January 19, 2023

In early December, Seaport neighbors Vertex and Entrada announced a global collaboration focused on discovering and developing therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage preclinical development. Entrada’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics […]

Moderna’s RSV Vaccine Shows Positive Trial Results

Posted by ISPE Boston
On January 19, 2023

Moderna has announced positive topline data from its Phase 3 trial of its vaccine candidate, mRNA-1345, targeting respiratory syncytial virus (RSV) in older adults. The primary efficacy endpoints have been met, including vaccine efficacy (VE) of 83.7% against RSV-associated lower respiratory tract disease. Based on these results, Moderna intends to submit for regulatory approval in […]

Page 26 of 118«‹24 252627 28 ›»